Metastatic Nasopharyngeal Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 7, 2023

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Metastatic Nasopharyngeal Carcinoma
Interventions
DRUG

Penplimab Injection

"Penplimab Injection: Intravenous infusion of Penplimab 200 mg Q3W, with a 3-week treatment cycle.~Anlotinib Hydrochloride Capsules: 10 mg, taken orally on an empty stomach before breakfast once a day (the daily medication time should be the same as much as possible), delivered in warm water, continuously used for 2 weeks and stopped for 1 week, with a treatment cycle of 3 weeks.~Gemcitabine injection: Intravenous infusion of 1000mg/m2, administered on the 1st and 8th days of each cycle, 3 weeks per cycle for 4-6 cycles."

DRUG

Antitinib Hydrochloride Capsules

10 mg, taken orally on an empty stomach before breakfast once a day (the daily medication time should be the same as much as possible), delivered in warm water, continuously used for 2 weeks and stopped for 1 week, with a treatment cycle of 3 weeks.

DRUG

Gemcitabine

Intravenous infusion of 1000mg/m2, administered on the 1st and 8th days of each cycle, 3 weeks per cycle for 4-6 cycles.

Trial Locations (1)

325000

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Chen Xiaozhong

OTHER